Loading
Loading
Research Overview
Long-acting amylin analogue; activates amylin receptors (AMY1–3) in the brainstem and hypothalamus to reduce food intake, slow gastric emptying, and suppress glucagon. Combined with semaglutide as 'CagriSema' in clinical trials.
Overview
Cagrilintide is a fatty acid-acylated amylin analogue designed to extend the plasma half-life of amylin receptor agonist activity. Preclinical research has examined its effects on satiety-related neural circuits, gastric emptying rate, and circulating metabolic markers in animal model systems.
The combination of cagrilintide with semaglutide, studied as CagriSema, has been an active area of preclinical investigation. Researchers have used animal models to examine whether amylin and GLP-1 receptor co-activation produces additive or synergistic effects on body weight, food intake, and metabolic parameters.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, cagrilintide (long-acting amylin analogue) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Long-acting amylin analogue; activates amylin receptors (AMY1–3) in the brainstem and hypothalamus to reduce food intake, slow gastric emptying, and suppress glucagon. Combined with semaglutide as 'CagriSema' in clinical trials.
Support
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.